Derbend Asset Management - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 409 filers reported holding CRISPR THERAPEUTICS AG in Q3 2023. The put-call ratio across all filers is 1.08 and the average weighting 0.1%.

Quarter-by-quarter ownership
Derbend Asset Management ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q2 2023$234,384
-21.9%
4,175
-8.9%
0.16%
-33.9%
Q3 2022$300,000
+5.6%
4,585
-1.8%
0.24%
+0.8%
Q2 2022$284,000
-68.0%
4,667
-60.2%
0.24%
-72.7%
Q1 2022$888,0000.0%11,7140.0%0.87%0.0%
Q4 2021$888,000
-43.2%
11,714
-16.1%
0.87%
-40.9%
Q3 2021$1,563,000
-22.7%
13,963
+11.7%
1.47%
-22.1%
Q2 2021$2,023,00012,4981.88%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q3 2023
NameSharesValueWeighting ↓
Versant Venture Management, LLC 498,558$31,294,00031.24%
NEA Management Company, LLC 1,590,002$365,593,00010.56%
Ariose Capital Management Ltd 37,900$2,379,0009.30%
ARK Investment Management 9,404,071$590,294,0002.46%
NIA IMPACT ADVISORS, LLC 80,082$5,027,0002.44%
Nikko Asset Management Americas, Inc. 4,619,747$291,044,0002.14%
PLUSTICK MANAGEMENT LLC 50,000$3,139,0001.98%
Integral Health Asset Management, LLC 120,000$7,532,0001.96%
Valiant Capital Management, L.P. 240,683$15,108,0001.73%
Deuterium Capital Management, LLC 18,000$1,130,0001.45%
View complete list of CRISPR THERAPEUTICS AG shareholders